Interim report January – September 2021
The period in summary
Third quarter July 1 – September 30, 2021
· On August 16th the European Commission granted a Marketing Authorisation for Strangvac within the European Union. · The Veterinary Medicines Directorate (VMD) of the United Kingdom granted a Marketing Authorisation for Strangvac within the UK on September 17th. · On August 23rd the Norwegian Medicines Agency (NoMA), granted a marketing authorisation for Strangvac in Norway.
Figures in brackets indicate outcome for the corresponding period of the previous financial year. The financial information presented